Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

G1 Therapeutics Inc (GTHX)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow G1 Therapeutics's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
3.860 -0.130    -3.26%
16:00:04 - Closed. Currency in USD ( Disclaimer )
After Hours
3.930
+0.070
+1.813%
16:16:09 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 538,064
  • Bid/Ask: 3.840 / 3.980
  • Day's Range: 3.775 - 3.930
G1 Therapeutics 3.860 -0.130 -3.26%

G1 Therapeutics Inc Company Profile

 
Get an in-depth profile of G1 Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

100

Equity Type

ORD

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Contact Information

Address 700 Park Offices Drive Suite 200
Research Triangle Park, 27709
United States
Phone 919 213 9835
Fax 919 741 5830
Web www.g1therapeutics.com

Top Executives

Name Age Since Title
Garry A. Nicholson 66 2018 Independent Chairman of the Board
John E. Bailey 56 2020 CEO, President & Director
Glenn P. Muir 64 2015 Independent Director
Jacks Lee 58 2022 Independent Director
Seth A. Rudnick 74 2014 Member of Clinical Advisory Board
Norman E. Sharpless 56 2022 Director
Kwok-Kin Wong - - Co-Founder & Member of Scientific Advisory Board
Gary H. Lyman 77 - Scientific & Clinical Advisor
Geoffrey I. Shapiro - - Scientific & Clinical Advisor
Alicia Secor 60 2021 Independent Director
Cynthia L. Flowers 63 2018 Independent Director
Donald P. McDonnell - - Scientific & Clinical Advisor
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

GTHX Comments

Write your thoughts about G1 Therapeutics Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
ali kaya
ali kaya Sep 13, 2023 6:19AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
junk
Reply
0 0
Report
Dan Seth
aks1447 Aug 21, 2023 9:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Anyone still holding?
Reply
1 1
Report
Marat Aysin
Marat Aysin Aug 07, 2022 8:34PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
So someone is pumping up again. Well, wish I had invested at 4 USD. It still can climb... but risky enough
Reply
2 0
Report
Лев Карелин
Лев Карелин Mar 10, 2022 3:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
When the rocket? :)
Reply
0 0
Report
Igor Vakarchuk
Igor Vakarchuk Mar 10, 2022 3:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The price will rise to $ 45-55 in May!
Reply
1 0
Report
Cristina Danalachi
Cristina Danalachi Mar 10, 2022 3:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
wich year?
Reply
0 0
Report
Cristina Danalachi
Cristina Danalachi Mar 10, 2022 3:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
which year?
Reply
0 0
Report
fbks fiddler
fbks fiddler Nov 12, 2021 2:16PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
With j-code in effect and resounding approval of prescribers looking for revenue of $5.5m minimum on Cosela sales alone
Reply
0 0
Report
Ivan Zorin
Ivan Zorin Sep 17, 2021 9:01PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Bought for 15.0In case of fail, money will help sbdy )
Reply
0 0
Report
Medved Show Timka
Medved Show Timka Jul 29, 2021 12:31PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
12 next
Reply
1 7
Report
Rockfeller John
Rockfeller John Jul 29, 2021 12:31PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Bravo! Midved show time shishka! 👍
Reply
0 0
Report
just trader
just trader Jun 22, 2021 8:18AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
G1 Therapeutics Cosela is FDA approved drug. One course cost 34 000$ and current target audince is more than 30 000 patients per year. Given near 80% margin it results in potential operationg profit per year of more than 800 mln (34k x 30k x 0,8). But with further FDA approvals for another cancer types target audience will be more than 400k patients. So, you can recalculate potential profitability.Main reason why i'm writing this is that current capitalisation is near 900mln. Analysts target prices are 2,5-4x from current price, but I think that it is much more undervalued and at least 6-7x rise will just give reasonable price to this company. What do you think of this?
Reply
5 0
Report
fbks fiddler
fbks fiddler Jun 22, 2021 8:18AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
expecting 4-5m in revenue Q3 depending on delta variant with respect to sales face time. exceedingly more after permenant j-code takes effect in oct.
Reply
0 0
Report
Vedit Kamiloglu
Vedit Kamiloglu May 26, 2021 1:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Fasten your seatbelts!
Reply
1 0
Report
Medved Show Timka
Medved Show Timka May 19, 2021 8:19AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
19.5 next week
Reply
0 0
Report
John Rockfeller
John Rockfeller May 19, 2021 8:19AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
No timka, no!
Reply
0 0
Report
John Rockfeller
John Rockfeller May 19, 2021 8:19AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ne armageddon' tut
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email